• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Strata Skin Sciences Inc. (Amendment)

    2/14/22 8:23:08 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care
    Get the next $SSKN alert in real time by email
    SC 13G/A 1 tm222623d36_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

    STRATA SKIN SCIENCES, INC.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    86272A206

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    ¨ Rule 13d-1(c)

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages

    Page 1 of 7 Pages

     

     

     

     

     

    CUSIP NO. 86272A206 Page 2 of 7

     

    CUSIP No.  86272A206
    (1) Names of reporting persons Nantahala Capital Management, LLC
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization MA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 4,575,812
    (7) Sole dispositive power 0
    (8) Shared dispositive power 4,575,812
    (9) Aggregate amount beneficially owned by each reporting person 4,575,812
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 13.3%
    (12) Type of reporting person (see instructions) IA

     

     

     

    CUSIP NO. 86272A206 Page 3 of 7

      

    CUSIP No.  86272A206
    (1) Names of reporting persons Wilmot B. Harkey
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 4,575,812
    (7) Sole dispositive power 0
    (8) Shared dispositive power 4,575,812
    (9) Aggregate amount beneficially owned by each reporting person 4,575,812
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 13.3%
    (12) Type of reporting person (see instructions) HC

     

     

     

    CUSIP NO. 86272A206 Page 4 of 7

      

    CUSIP No.  86272A206
    (1) Names of reporting persons Daniel Mack
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 4,575,812
    (7) Sole dispositive power 0
    (8) Shared dispositive power 4,575,812
    (9) Aggregate amount beneficially owned by each reporting person 4,575,812
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 13.3%
    (12) Type of reporting person (see instructions) HC

     

    Item 1(a). Name of Issuer:
       
      STRATA SKIN SCIENCES, INC. (the “Issuer”).
       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
      5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania 19044
       
    Item 2(a). Name of Person Filing
       
     

    Nantahala Capital Management, LLC (“Nantahala”)

    Wilmot B. Harkey

    Daniel Mack (together the “Reporting Persons”)

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
     

    130 Main St. 2nd Floor

    New Canaan, CT 06840

     

    Item 2(c). Citizenship:
       
     

    Nantahala is a Massachusetts limited liability company.

    Each of Messrs. Harkey and Mack is a citizen of the United States of America.

       
    Item 2(d).

    Title of Class of Securities:

     

     

    Common Stock, $0.001 par value per share (the “Shares”).

     

     

     

     

    CUSIP NO. 86272A206 Page 5 of 7

     

    Item 2(e).

    CUSIP Number:
     

     

    86272A206

     

    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g) xA parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4.

     

    Ownership:

       
    Item 4(a).

    Amount Beneficially Owned:

     

    As of December 31, 2021, Nantahala may be deemed to be the beneficial owner of 4,575,812 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares.

       
    Item 4(b).

    Percent of Class:

     

    As of December 31, 2021, each of the Reporting Persons may be deemed to be the beneficial owner of 13.3% of the total number of Shares outstanding (based upon information provided by the Issuer on the Issuer’s S-3 filed January 13, 2022, there were 34,364,679 Shares outstanding as of December 31, 2021).

       

     

     

     

    CUSIP NO. 86272A206 Page 6 of 7

     

    Item 4(c). Number of shares as to which such person has:

     

     

    Nantahala Capital Management, LLC

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 4,575,812
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 4,575,812
       
     

    Each of Messrs. Harkey and Mack

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 4,575,812
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 4,575,812

     

    Item 5. Ownership of Five Percent or Less of a Class:
       
      This Item 5 is not applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      Nantahala Capital Partners SI, LP, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, approximately 5.1% of the outstanding shares of common stock beneficially owned by Nantahala reported herein.  
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E).  See Item 4(a).
       
    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
       
    Item 10. Certification:

     

     

    By signing below each Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

    CUSIP NO. 86272A206 Page 7 of 7

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

     

    Date:  February 14, 2022 NANTAHALA CAPITAL MANAGEMENT, LLC
       
      By: /s/ Taki Vasilakis
        Taki Vasilakis
        Chief Compliance Officer
       
      /s/ Wilmot B. Harkey
      Wilmot B. Harkey
       
      /s/ Daniel Mack
      Daniel Mack

     

     

    Get the next $SSKN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SSKN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SSKN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Geiger Uri bought $723,999 worth of shares (230,573 units at $3.14) (SEC Form 4)

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      7/17/24 5:08:57 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Large owner Accelmed Partners, L.P. bought $723,999 worth of shares (230,573 units at $3.14), increasing direct ownership by 19% to 1,441,835 units (SEC Form 4)

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      7/17/24 5:08:11 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Rafaeli Dolev bought $59,974 worth of shares (19,100 units at $3.14), increasing direct ownership by 15% to 143,156 units (SEC Form 4)

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      7/17/24 5:01:09 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Leadership Updates

    Live Leadership Updates

    See more
    • Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

      Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

      11/28/23 8:30:00 AM ET
      $APYX
      $PDSB
      $SSKN
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • STRATA Skin Sciences Appoints Dr. Uri Geiger to Chairman of its Board of Directors

      HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation. "I'm honored to assume the role of Chairman at this pivotal moment in STRATA's growth," said Dr. Uri Geiger, Chairman of STRATA's Board of Directors. "I look forward to levera

      6/30/23 8:00:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences Appoints Patricia S. Walker, M.D., Ph.D. to its Board of Directors

      HORSHAM, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that effective today, Patricia S. Walker M.D., PhD. has been appointed to its Board of Directors. Dr. Walker's vast experience includes more than 35 years as a practicing dermatologist and as a corporate leader in the medical dermatology, medical aesthetics and pharmaceutical industries, executing clinical research and strategic initiatives for a wide range of companies and educational institutions. "We are delighted to welcome Patty to STRAT

      2/14/22 4:05:00 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    SEC Filings

    See more
    • Strata Skin Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)

      5/14/25 5:25:17 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form 10-K/A filed by Strata Skin Sciences Inc.

      10-K/A - STRATA Skin Sciences, Inc. (0001051514) (Filer)

      4/30/25 4:33:20 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Strata Skin Sciences Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)

      4/25/25 4:30:45 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Gov Shmuel

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      5/15/25 5:21:12 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Accounting Officer Gillings John T

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      5/15/25 5:14:28 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Rafaeli Dolev

      4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

      5/15/25 5:09:40 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Strata Skin Sciences Inc.

      SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

      11/14/24 2:04:43 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Strata Skin Sciences Inc.

      SC 13D/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

      7/18/24 7:42:09 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Strata Skin Sciences Inc. (Amendment)

      SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

      2/14/24 4:51:41 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Financials

    Live finance-specific insights

    See more
    • STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update. First Quarter 2025 Financial Highlights Revenue in the first quarter of 2025 was $6.8 million, up 1% Global net recurring XTRAC® revenue in the first quarter was $4.5 million vs. $4.6 million in the prior year period, with international growth of 27% offsetting a 4% decline in the domestic marketAverage net revenue per dome

      5/14/25 4:05:00 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences to Report First Quarter 2025 Financial Results on May 14, 2025 and Provide Corporate Update

      HORSHAM, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report first quarter 2025 financial results on Wednesday, May 14, 2025 after the market close. STRATA management will subsequently host a conference call at 5:00 p.m. ET on Wednesday, May 14, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interested pa

      5/7/25 8:15:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences to Report Fourth Quarter and Year End 2024 Financial Results on March 27, 2025 and Provide Corporate Update

      HORSHAM, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report fourth quarter and year end 2024 financial results on Thursday, March 27, 2025 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Thursday, March 27, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interest

      3/21/25 1:43:43 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care

    $SSKN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Reimbursement of 308nm Excimer Laser Treatments, Unlocking Access for Millions with Inflammatory and Auto-Immune Skin Diseases

      HORSHAM, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to advancing dermatologic care through innovation, announces that the American Medical Association (AMA) CPT Editorial Panel, in its May, 2025 summary of panel actions (May 2025: CPT® Editorial Summary of Panel Actions | AMA) has accepted revision to CPT codes 96920-96922, expanding reimbursement eligibility for excimer laser treatments to include multiple inflammatory and auto-immune skin conditions beyond their original psoriasis indication. This change reflects over 20 years of clinical evidence and real-world use of STRATA's XTRAC®

      5/19/25 8:00:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update. First Quarter 2025 Financial Highlights Revenue in the first quarter of 2025 was $6.8 million, up 1% Global net recurring XTRAC® revenue in the first quarter was $4.5 million vs. $4.6 million in the prior year period, with international growth of 27% offsetting a 4% decline in the domestic marketAverage net revenue per dome

      5/14/25 4:05:00 PM ET
      $SSKN
      Medical/Dental Instruments
      Health Care
    • STRATA Skin Sciences to Participate in the D. Boral Capital Inaugural Global Conference

      HORSHAM, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will participate in the D. Boral Capital Inaugural Global Conference. The conference is being held on May 14, 2025, at The Plaza Hotel, 768 Fifth Avenue, New York, NY 10019. President and Chief Executive Officer Dr. Dolev Rafaeli will be hosting one-on-one meetings on May 14, 2025 from 9:00 AM to 3:00 PM (ET). To register for one-on-one meetings with management at The Plaza Hotel in New York City, intereste

      5/8/25 8:15:00 AM ET
      $SSKN
      Medical/Dental Instruments
      Health Care